top of page
ULTOMIRIS (ravulizumab-cwvz) for the Treatment of Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Tue, Jun 25
|The Capital Grille
The first and only long-acting complement inhibitor that provides immediate and complete C5 inhibition for 8 weeks
Registration is Closed
See other events
Time & Location
Jun 25, 2019, 6:00 PM – 8:00 PM
The Capital Grille, 900 Boylston St, Boston, MA 02115, USA
Guests
About The Event
Presentation by Christa Roe, MA, BS, RN
Yale University, Yale School of Medicine
New Haven, Connecticut
Indication:
ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Please contact Erin Gillis at 617-413-1067 or at Erin.gillis@alexion.com. Please refer to meeting ID number: ALX0002399.
bottom of page